BACKGROUND: Several clinical studies have shown that recombinant human erythropoietin (rHuEpo) can ameliorate the anemia associated with hematologic malignancies and solid tumors. On the other hand, only a few studies have been performed to investigate whether rHuEpo can affect or modulate the growth of malignant cells. MATERIALS AND METHODS: We studied the effects of rHuEpo (0.5 to 10 IU/mL) on clonogenic growth and cell kinetics in ten cell lines derived from both hematologic malignancies and solid tumors. Clonogenic assays were performed by plating 5 x 10(3) cells in agar, while the percentage of cells in S phase was assessed by DNA flow cytometry. RESULTS: rHuEpo did not affect either in vitro colony formation or S phase percentage in the human erythroid cell lines K-562 and HEL expressing erythropoietin receptors (< 40 receptors per cell). No effect of rHuEpo was observed in the remaining hematopoietic cell lines or in five solid tumor cell lines. CONCLUSIONS: These findings indicate that rHuEpo, even at very high concentrations, does not affect either clonogenic growth or DNA synthesis in the cell lines tested. Available evidence suggests that rHuEpo can be safely employed in all malignancies except acute myeloid leukemia.
BACKGROUND: Several clinical studies have shown that recombinant humanerythropoietin (rHuEpo) can ameliorate the anemia associated with hematologic malignancies and solid tumors. On the other hand, only a few studies have been performed to investigate whether rHuEpo can affect or modulate the growth of malignant cells. MATERIALS AND METHODS: We studied the effects of rHuEpo (0.5 to 10 IU/mL) on clonogenic growth and cell kinetics in ten cell lines derived from both hematologic malignancies and solid tumors. Clonogenic assays were performed by plating 5 x 10(3) cells in agar, while the percentage of cells in S phase was assessed by DNA flow cytometry. RESULTS: rHuEpo did not affect either in vitro colony formation or S phase percentage in the human erythroid cell lines K-562 and HEL expressing erythropoietin receptors (< 40 receptors per cell). No effect of rHuEpo was observed in the remaining hematopoietic cell lines or in five solid tumor cell lines. CONCLUSIONS: These findings indicate that rHuEpo, even at very high concentrations, does not affect either clonogenic growth or DNA synthesis in the cell lines tested. Available evidence suggests that rHuEpo can be safely employed in all malignancies except acute myeloid leukemia.
Authors: Alberto Biete Sola; Felipe A Calvo Manuel; Bernardino Clavo Varas; Cristina Fernández Pérez; Carmen Porto Vázquez; Alejandro de la Torre Tomás; Almudena Zapatero Laborda Journal: Clin Transl Oncol Date: 2005-09 Impact factor: 3.405
Authors: Cristiana Lo Nigro; Monica Maffi; Jean Louis Fischel; Martino Monteverde; Paolo Catarsi; Federica Tonissi; Laura Lattanzio; Michela Riba; Marie-Christine Etienne-Grimaldi; Patricia Formento; Gerard Milano; Marco Merlano Journal: J Cancer Res Clin Oncol Date: 2009-06-05 Impact factor: 4.553
Authors: Anita Rózsás; Judit Berta; Lívia Rojkó; László Z Horváth; Magdolna Keszthelyi; István Kenessey; Viktória László; Walter Berger; Michael Grusch; Mir Alireza Hoda; Szilvia Török; Walter Klepetko; Ferenc Rényi-Vámos; Balázs Hegedűs; Balázs Döme; József Tóvári Journal: PLoS One Date: 2013-10-14 Impact factor: 3.240
Authors: A M Sinclair; N Rogers; L Busse; I Archibeque; W Brown; P D Kassner; J E V Watson; G E Arnold; K C Q Nguyen; S Powers; S Elliott Journal: Br J Cancer Date: 2008-03-18 Impact factor: 7.640